Research
Hormonal
AgRP neuron hyperactivity contributes to chronic insulin resistance and obesity by inducing brown adipose tissue-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue.
This mechanism explains why some individuals with obesity struggle with insulin resistance beyond just fat mass. It suggests that targeting the AgRP-myostatin pathway could be a therapeutic strategy, although current treatments focus more broadly on GLP-1 and MC4R pathways.
ModerateSupportsMEDIUM confidence
Sustained AgRP hyperactivity induces brown adipose tissue (BAT)-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue. Genetic ablation of myostatin, specifically in BAT, restores insulin-stimulated glucose uptake, demonstrating a causal role for the AgRP-myostatin axis in metabolic dysregulation (Steculorum et al., 2016).
Why this rating
Based on animal studies (mice) cited in a review.
Source
Role of hypothalamus function in metabolic diseases and its potential mechanisms
Xinyu Zhang et al. · PeerJ · 2025
DOI 10.7717/peerj.19532
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists and MC4R modulators are emerging therapeutic strategies that target hypothalamic pathways to treat metabolic diseases.Good
- Dysregulation of hypothalamic nuclei (specifically AgRP and POMC neurons in the arcuate nucleus) is a primary driver of obesity and type 2 diabetes through mechanisms involving insulin resistance, hyperphagia, and disrupted glucose sensing.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →